Human Fibrinogen Concentrate Market Research, 2035
The global human fibrinogen concentrate market was valued at $0.8 billion in 2023, and is projected to reach $2.9 billion by 2035, growing at a CAGR of 11% from 2024 to 2035. The Human Fibrinogen Concentrate Market has grown due to rise in elderly people, who are prone to chronic diseases, and increase in diseases such as heart attacks, strokes, tumors, and blockages in blood vessels, which further lead to more surgeries. Rise in sports injuries and road accidents is also increasing the demand for human fibrinogen product. Hence, such factors boost the growth of the Human Fibrinogen Concentrate Market. For instance, according to the Sports and Fitness Industry Association, about 30 million children and teens participated in some form of organized sports in the U.S., in 2021, and this led to more than 3.5 million injuries in 2021.
Human fibrinogen concentrate is a hematological agent that works by replacing a certain protein in the blood that helps with blood clotting, specifically for patients with congenital fibrinogen deficiency (afibrinogenemia or hypofibrinogenemia). It is used to control acute bleeding episodes in patients with congenital fibrinogen deficiency.
Key Takeaways
- By indication, the congenital fibrinogen deficiency segment dominated the global human fibrinogen concentrate market size in 2023.
- By form, the liquid form segment acquired a major share in the global human fibrinogen concentrate market size in 2023.
- By end user, the hospitals segment acquired a major share in the global market in 2023.
- By region, North America dominated the market in terms of revenue in 2023.
Market Dynamics
Human fibrinogen is currently used in several surgical specialties, including cardiovascular surgery, urological surgery, pulmonary surgery, wound management, orthopedic surgery, ophthalmic surgery, neurosurgery, plastic and reconstructive surgery, and dental surgery to reduce blood loss. Human Fibrinogen is used for sealing tissues during surgery. Human fibrinogen helps in reducing blood loss and to stop blood flow during surgeries and in wound management. Human fibrinogen mimics the final steps of the physiological coagulation cascade to form a fibrin clot. The use of human fibrinogen is expected to reduce perioperative and postoperative complications by reducing fluid leakage, air leakage, and by preventing fistulae formation. Human fibrinogen has a unique physiologic action, and the resulting fibrin clot is fully degraded by the body's natural wound healing process.
The market expansion is further propelled by the introduction of novel human fibrinogen products for specific indications. For instance, in addition to Octapharma's Fibryga, RIASTAP stands as a revolutionary fibrinogen replacement therapy, boasting rapid reconstitution properties and the ability to swiftly restore fibrinogen levels, particularly crucial in managing acute bleeding episodes. In 2020, Octapharma’s Fibryga received Health Canada approval to treat acquired fibrinogen deficiency (AFD) in surgical settings. Fibryga is a purified, lyophilized human fibrinogen concentrate for intravenous infusion, with a rapid reconstitution device and ability to infuse advised dose in 10 minutes for effective correction of fibrinogen deficiency.
However, few restraints such as stringent regulatory requirements for product approval coupled with high cost associated with fibrinogen concentrate therapy might restrict the market growth. Further, limited availability of skilled healthcare professionals for administration, especially in underdeveloped and developing economies, is expected to restrain the market growth during the forecast period.
Segments Overview
The Human Fibrinogen Concentrate Market is segmented into indication, form, end user, and region. By indication, the market is segmented into congenital fibrinogen deficiency and surgical procedures. By form, the market is segmented into lyophilized, powder, and liquid. By end user, the market is segmented into hospitals, ambulatory surgical centers (ASCs), and others. Region-wise, the Human Fibrinogen Concentrate industry is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
By Indication
By indication, the congenital fibrinogen deficiency segment dominated the human fibrinogen concentrate market share in 2023 and is expected to continue this trend during the forecast period. Congenital fibrinogen deficiency is growing in developing and developed countries wherein consanguineous marriages are common and is often diagnosed in the newborn period. For instance, Pakistan has leading population of congenital fibrinogen deficiency, which is then followed by countries such as Iran, Slovakia, Ireland, and the UK.
By Form
By form, the lyophilized segment dominated the market in 2023 and is expected to continue this trend during the forecast period. The lyophilized form of human fibrinogen is expected to dominate the Human Fibrinogen Concentrate industry in 2023 due to its rise in use in patients with bleeding problems who lack congenital fibrinogen. For instance, according to the National Bleeding Disorders Foundation in 2024, between 30,000 and 33,000 people in the U.S. were thought to live with hemophilia and the number is expected to increase by at least 2-3% per year.
By End User
By end user, the hospitals segment dominated the human fibrinogen concentrate market share in 2023. Utilization of human fibrinogen is more in hospital settings as compared to other healthcare settings such as ASCs and clinics. This is due to its critical role in blood clotting, its effectiveness in treating bleeding disorders, and its association with mortality and organ failure in trauma patients. Furthermore, according to the WHO, between 2015 and 2050, proportion of the world's population is expected to nearly double from 12% to 22%, and by 2050, 80% of older people are expected to be from China and India. Thus, rise in geriatric population being more susceptible toward developing liver cirrhosis, kidney failure, heart failure, cancer, cholangiocarcinoma, & hepatic metastatic cancer, chronic disease, is anticipated to drive the demand for human fibrinogen.
By Region
Region-wise, North America dominated the market in 2023, owing to rise in the number of chronic heart disease cases, the presence of key players, robust healthcare infrastructure, and rise in healthcare expenditure. However, Asia-Pacific is expected to grow with a faster CAGR during the human fibrinogen concentrate market analysis period. This is mainly due to the rapid growth rate in pharmaceutical and biologics industry coupled with increase in medical tourism which in turn has led to increased surgeries thereby driving the Asia Pacific Human Fibrinogen Concentrate Market growth.
Competitive Analysis
Major players have adopted product development and launch as their key strategy. For instance, in February 2024, Biotest’s positive topline results from AdFIrst, its phase 3 clinical trial of its fibrinogen concentrate (FC), BT524, advance this potential treatment for acquired fibrinogen deficiency (AFD), an underserved growth market.
Recent Developments in Human Fibrinogen Concentrate Industry
- In February 2022, Corza entered a long- term agreement with Takeda Pharmaceutical Company, under which Takeda is expected to manufacture and supply TachoSil products to Corza.
- In June 2019, Grifols launched plasma protein based VISTASEAL, a fibrin sealant used to control surgical bleeding.
- In December 2019, Grifols collaborated with Ethicon, a Johnson and Johnson medical device company for commercializing and distributing VISTASEAL in the U.S.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the human fibrinogen concentrate market analysis from 2023 to 2035 to identify the prevailing human fibrinogen concentrate market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the human fibrinogen concentrate market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global human fibrinogen concentrate market trends, key players, market segments, application areas, and market growth strategies.
Human Fibrinogen Concentrate Market Report Highlights
| Aspects | Details |
 Market Size By 2035 | USD 2.9 billion |
 Growth Rate | CAGR of 11% |
 Forecast period | 2023 - 2035 |
 Report Pages | 280 |
 By Form |
|
 By End User |
|
 By Indication |
|
 By Region |
|
 Key Market Players | Octapharma AG, Intas Pharmaceuticals Limited, Shanghai RAAS Blood Products Co., Ltd., The LFB group, Grifols, S.A., CSL Limited |
Analyst Review
Analysts suggest that the utilization of human fibrinogen yields positive impacts on surgical outcomes, including enhanced time to hemostasis, reduced blood loss, and minimized complications. The Human Fibrinogen Concentrate Market has garnered significant interest within the healthcare industry due to several factors, including the increase in prevalence of chronic heart diseases, dental conditions, post-operative complications, a growing geriatric population, and rise incidences of chronic diseases globally.
Surge in demand for human fibrinogen spans a wide array of surgical procedures, expected to substantially propel the market growth. Moreover, upsurge in road accidents contributes to a higher volume of surgeries and subsequent adoption of human fibrinogen. However, the market growth is hampered by the high cost of fibrin sealant products. Conversely, untapped medical needs in developing nations present lucrative opportunities for market expansion.
In terms of revenue, North America is poised to witness the most significant growth, fueled by increase in various organ cancer surgeries, a robust healthcare infrastructure, presence of key industry players, and rise in healthcare spending. Conversely, Asia-Pacific is anticipated to experience noteworthy growth due to factors such as a rising geriatric population, unmet medical needs, initiatives by governmental and non-governmental organizations to promote awareness about fibrin sealant usage in surgeries, and increased public-private investments in the healthcare sector.
Increasing incidence of bleeding disorders coupled with the growing demand for fibrinogen concentrates in surgeries are the key drivers in the human fibrinogen market.
Human fibrinogen is a protein found in blood plasma and plays a crucial role in blood clotting, a process known as coagulation. It is one of the key components involved in the formation of blood clots, which is essential for stopping bleeding when a blood vessel is injured.
Yes, competitive landscape included in the human fibrinogen market report study
Baxter, CSL Behring and Octapharma are the 3 major companies operating in the Human Fibrinogen market
The global Human Fibrinogen Concentrate Market size was valued at $0.8 billion in 2023 and is projected to reach $2.9 billion by 2035, registering a CAGR of 11% from 2023 to 2035.
North America dominated the market in terms of revenue in 2023
The congenital fibrinogen deficiency segment dominated the global market in 2023
Growing demand for fibrinogen products in surgeries and shift towards recombinant fibrinogen are the 2 major trends in Human Fibrinogen Market
Loading Table Of Content...
Loading Research Methodology...
